BioSpace News Archive

Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability

Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline

Industry Veterans Will Lead Planned Launch of Device Designed to Provide a Safe, Rapid Solution for Abnormal Postpartum Uterine Bleeding

Bristol Myers Squibb announced that its Board of Directors has elected two new independent directors, Ms. Paula A. Price and Mr. Derica W. Rice, who will join the Board, effective September 1, 2020.

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced the pricing of an underwritten public offering of 21,666,667 shares of its common stock at a public offering price of $3.00 per share.

Leading institutional investors commit $320 million through a common stock private investment in public equity (“PIPE”) led by Bain Capital, Perceptive Advisors, Pfizer Inc. and other top-tier healthcare investors

Lexicon Pharmaceuticals, Inc. and TerSera Therapeutics LLC announced that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, title and interest in XERMELO®.

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced that Wayne A.I. Frederick, M.D., has been elected to serve on the company’s board of directors.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its second quarter 2020 financial results and operational highlights in a conference call on August 6, 2020 at 8 a.m. ET. To join the call: U.S. callers should dial 1-877-317-6789 and international callers should dial +1-412-317-6789, approximately f

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.